KR20160111925A - 자살 위험과 연관된 유전적 마커 및 그의 사용 방법 - Google Patents
자살 위험과 연관된 유전적 마커 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR20160111925A KR20160111925A KR1020167019492A KR20167019492A KR20160111925A KR 20160111925 A KR20160111925 A KR 20160111925A KR 1020167019492 A KR1020167019492 A KR 1020167019492A KR 20167019492 A KR20167019492 A KR 20167019492A KR 20160111925 A KR20160111925 A KR 20160111925A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- subject
- suicide
- combination
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010010144 Completed suicide Diseases 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 76
- 230000002068 genetic effect Effects 0.000 title claims description 26
- 239000003550 marker Substances 0.000 claims abstract description 51
- 108700028369 Alleles Proteins 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 47
- 125000003729 nucleotide group Chemical group 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 46
- 208000024891 symptom Diseases 0.000 claims description 37
- 239000000523 sample Substances 0.000 claims description 35
- 208000020016 psychiatric disease Diseases 0.000 claims description 32
- 230000000295 complement effect Effects 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 208000020925 Bipolar disease Diseases 0.000 claims description 18
- 208000028017 Psychotic disease Diseases 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 201000000980 schizophrenia Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 208000022610 schizoaffective disease Diseases 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 238000009396 hybridization Methods 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 238000001712 DNA sequencing Methods 0.000 claims description 6
- 230000000561 anti-psychotic effect Effects 0.000 claims description 6
- 229960004170 clozapine Drugs 0.000 claims description 6
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 6
- 208000022821 personality disease Diseases 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 208000012672 seasonal affective disease Diseases 0.000 claims description 6
- 206010012239 Delusion Diseases 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 208000004547 Hallucinations Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 231100000868 delusion Toxicity 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000013546 non-drug therapy Methods 0.000 claims description 4
- 206010022998 Irritability Diseases 0.000 claims description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 206010034158 Pathological gambling Diseases 0.000 claims description 3
- 108010010677 Phosphodiesterase I Proteins 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 238000011888 autopsy Methods 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 238000001523 electrospinning Methods 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 229960003299 ketamine Drugs 0.000 claims description 3
- 229960001078 lithium Drugs 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 229940127237 mood stabilizer Drugs 0.000 claims description 3
- 239000004050 mood stabilizer Substances 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 201000009032 substance abuse Diseases 0.000 claims description 3
- 231100000736 substance abuse Toxicity 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 238000010222 PCR analysis Methods 0.000 claims description 2
- 230000016571 aggressive behavior Effects 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 238000013542 behavioral therapy Methods 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000003271 compound fluorescence assay Methods 0.000 claims description 2
- 238000009223 counseling Methods 0.000 claims description 2
- 238000009228 dialectical behavior therapy Methods 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 206010042464 Suicide attempt Diseases 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010042458 Suicidal ideation Diseases 0.000 description 3
- -1 but not limited to Chemical compound 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108091065234 miR-5583-1 stem-loop Proteins 0.000 description 3
- 108091042709 miR-5583-2 stem-loop Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100022734 Acyl carrier protein, mitochondrial Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 2
- 101000611240 Homo sapiens Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 description 2
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 2
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 102100037026 Peptidyl-prolyl cis-trans isomerase FKBP5 Human genes 0.000 description 2
- 206010065604 Suicidal behaviour Diseases 0.000 description 2
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 2
- 102100026084 Syndecan-3 Human genes 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 101150096290 ADRB1 gene Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 102100040794 Beta-1 adrenergic receptor Human genes 0.000 description 1
- 101100256309 Caenorhabditis elegans sdc-3 gene Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 101150082209 Fmr1 gene Proteins 0.000 description 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 1
- 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 101000776351 Homo sapiens ALK and LTK ligand 2 Proteins 0.000 description 1
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 1
- 101000654564 Homo sapiens SH3 domain-containing YSC84-like protein 1 Proteins 0.000 description 1
- 101000831942 Homo sapiens Stomatin-like protein 3 Proteins 0.000 description 1
- 101000692107 Homo sapiens Syndecan-3 Proteins 0.000 description 1
- 206010021403 Illusion Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150065958 NR3C1 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150096336 PGR gene Proteins 0.000 description 1
- 102100032637 SH3 domain-containing YSC84-like protein 1 Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108090000068 Syndecan-3 Proteins 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- MLZKDXMVNKESMU-UHFFFAOYSA-N decanoic acid phenazine Chemical compound C(CCCCCCCCC)(=O)O.C1=CC=CC2=NC3=CC=CC=C3N=C12 MLZKDXMVNKESMU-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000013543 dialectical behavioral therapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091033202 miR-924 stem-loop Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- G06F19/22—
-
- G06F19/3487—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920332P | 2013-12-23 | 2013-12-23 | |
| US61/920,332 | 2013-12-23 | ||
| PCT/CA2014/051257 WO2015095967A1 (en) | 2013-12-23 | 2014-12-23 | Genetic markers associated with suicide risk and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160111925A true KR20160111925A (ko) | 2016-09-27 |
Family
ID=53477254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167019492A Withdrawn KR20160111925A (ko) | 2013-12-23 | 2014-12-23 | 자살 위험과 연관된 유전적 마커 및 그의 사용 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10435748B2 (https=) |
| EP (1) | EP3087203B1 (https=) |
| JP (1) | JP6679486B2 (https=) |
| KR (1) | KR20160111925A (https=) |
| CN (1) | CN106062213A (https=) |
| AU (1) | AU2014373588B2 (https=) |
| CA (1) | CA2934815C (https=) |
| IL (1) | IL246417B (https=) |
| SG (1) | SG11201605150YA (https=) |
| WO (1) | WO2015095967A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020235721A1 (ko) * | 2019-05-23 | 2020-11-26 | 울산과학기술원 | 다중 오믹스 분석을 이용한 우울증 또는 자살 위험 예측용 마커 발굴 방법, 우울증 또는 자살 위험 예측용 마커, 및 다중 오믹스 분석을 이용한 우울증 또는 자살 위험 예측 방법 |
| RU2853428C1 (ru) * | 2025-01-24 | 2025-12-23 | Федеральное государственное бюджетное учреждение "Центр стратегического планирования и управления медико-биологическими рисками здоровью" Федерального медико-биологического агентства | Способ прогнозирования развития психопатологических клинических проявлений |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2891830A1 (en) | 2015-05-15 | 2016-11-15 | Centre For Addiction And Mental Health | Genetic markers for suicide risk and related methods |
| JP2019520315A (ja) * | 2016-04-29 | 2019-07-18 | スパーナス ファーマシューティカルズ インコーポレイテッド | 衝動的攻撃性を監視、診断、及び治療する方法、システム、及びキット |
| CN108531569B (zh) * | 2017-03-03 | 2021-05-07 | 上海伯豪医学检验所有限公司 | 用于强迫症与精神分裂症、抑郁症甄别的基因标志物及其应用 |
| CN108148905A (zh) * | 2018-02-13 | 2018-06-12 | 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) | 一段可作为抑郁症标记物的序列 |
| WO2024215722A1 (en) * | 2023-04-10 | 2024-10-17 | Board Of Regents, The University Of Texas System | Methods and compositions for diagnosing and treating depression and suicide risk |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USH2191H1 (en) * | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US7361468B2 (en) * | 2004-07-02 | 2008-04-22 | Affymetrix, Inc. | Methods for genotyping polymorphisms in humans |
| US20120094855A1 (en) * | 2008-09-18 | 2012-04-19 | Max Planck Society | Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi) |
| EP2166112B1 (en) | 2008-09-18 | 2013-06-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for diagnosing predisposition for treatment emergent suicidal ideation |
| KR101249635B1 (ko) * | 2010-10-13 | 2013-04-01 | 서울대학교산학협력단 | 양극성 장애 진단용 ｅｇｒ2 유전자 ｓｎｐ, 그를 포함하는 마이크로어레이 및 키트 |
-
2014
- 2014-12-23 CN CN201480076117.6A patent/CN106062213A/zh active Pending
- 2014-12-23 WO PCT/CA2014/051257 patent/WO2015095967A1/en not_active Ceased
- 2014-12-23 SG SG11201605150YA patent/SG11201605150YA/en unknown
- 2014-12-23 CA CA2934815A patent/CA2934815C/en active Active
- 2014-12-23 JP JP2016542129A patent/JP6679486B2/ja active Active
- 2014-12-23 EP EP14873830.5A patent/EP3087203B1/en not_active Not-in-force
- 2014-12-23 KR KR1020167019492A patent/KR20160111925A/ko not_active Withdrawn
- 2014-12-23 US US15/107,437 patent/US10435748B2/en active Active
- 2014-12-23 AU AU2014373588A patent/AU2014373588B2/en not_active Ceased
-
2016
- 2016-06-23 IL IL246417A patent/IL246417B/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020235721A1 (ko) * | 2019-05-23 | 2020-11-26 | 울산과학기술원 | 다중 오믹스 분석을 이용한 우울증 또는 자살 위험 예측용 마커 발굴 방법, 우울증 또는 자살 위험 예측용 마커, 및 다중 오믹스 분석을 이용한 우울증 또는 자살 위험 예측 방법 |
| RU2853428C1 (ru) * | 2025-01-24 | 2025-12-23 | Федеральное государственное бюджетное учреждение "Центр стратегического планирования и управления медико-биологическими рисками здоровью" Федерального медико-биологического агентства | Способ прогнозирования развития психопатологических клинических проявлений |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3087203A1 (en) | 2016-11-02 |
| US20170002412A1 (en) | 2017-01-05 |
| CA2934815A1 (en) | 2015-07-02 |
| EP3087203A4 (en) | 2017-09-20 |
| WO2015095967A1 (en) | 2015-07-02 |
| SG11201605150YA (en) | 2016-07-28 |
| CN106062213A (zh) | 2016-10-26 |
| CA2934815C (en) | 2022-01-04 |
| AU2014373588B2 (en) | 2021-04-01 |
| AU2014373588A1 (en) | 2016-07-21 |
| JP2017503493A (ja) | 2017-02-02 |
| US10435748B2 (en) | 2019-10-08 |
| IL246417B (en) | 2020-08-31 |
| IL246417A0 (en) | 2016-08-31 |
| EP3087203B1 (en) | 2019-09-11 |
| JP6679486B2 (ja) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder | |
| Gao et al. | CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis | |
| Volpi et al. | Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia | |
| Zech et al. | Recessive mutations in the α3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia | |
| Pan et al. | Identification of TBX15 as an adipose master trans regulator of abdominal obesity genes | |
| KR20240095481A (ko) | Rnaset2를 통한 염증성 장 질환의 진단 방법 | |
| Venturi et al. | Osteogenesis imperfecta: clinical, biochemical and molecular findings | |
| EP2765227A2 (en) | Compositions and methods for identifying autism spectrum disorders | |
| KR20160111925A (ko) | 자살 위험과 연관된 유전적 마커 및 그의 사용 방법 | |
| JP2020089370A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法 | |
| Paisán‐Ruiz et al. | Homozygosity mapping through whole genome analysis identifies a COL18A1 mutation in an Indian family presenting with an autosomal recessive neurological disorder | |
| JP6524073B2 (ja) | 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 | |
| Korir et al. | A mutation in a splicing factor that causes retinitis pigmentosa has a transcriptome-wide effect on mRNA splicing | |
| AU2014336928A1 (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| Lohoff et al. | Association between polymorphisms in the vesicle-associated membrane protein-associated protein A (VAPA) gene on chromosome 18p and bipolar disorder | |
| Xuemei et al. | Peripheral SLC6A4 gene expression in obsessive-compulsive disorder in the Han Chinese population | |
| Porteous et al. | Genetics of schizophrenia and bipolar affective disorder: strategies to identify candidate genes | |
| JP7731540B2 (ja) | アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット | |
| JP5422805B2 (ja) | 新規糖尿病性腎症感受性遺伝子 | |
| WO2009036513A1 (en) | Diagnostic and therapeutic protocols | |
| HK1224705A1 (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| HK1224705B (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| CN108251519A (zh) | 轴前多指病的致病基因及其用途 | |
| Barr et al. | XIII World Congress on Psychiatric Genetics 2005 Sponsored by | |
| JPWO2010073544A1 (ja) | 冠状動脈疾患リスクの検査方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160718 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |